相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group
S. Stacchiotti et al.
ANNALS OF ONCOLOGY (2017)
MVX-ONCO-1 phase 1 final results of the first personalized cell-based immunotherapy using cell encapsulation technology
N. Mach et al.
ANNALS OF ONCOLOGY (2016)
Genomic Aberrations Frequently Alter Chromatin Regulatory Genes in Chordoma
Lu Wang et al.
GENES CHROMOSOMES & CANCER (2016)
Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels
Zsofia K. Stadler et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
Camille Hua et al.
JAMA DERMATOLOGY (2016)
Molecular targeted therapies in advanced or metastatic chordoma patients: Facts and hypotheses
Loic Lebellec et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
MVX-ONCO-1: First in man, Phase I clinical trial combining encapsulation cell technology and irradiated autologous tumor cells for personalized cell-based immunotherapy. Safety, feasibility and clinical outcome results
D. Migliorini et al.
EUROPEAN JOURNAL OF CANCER (2015)
Encapsulated Cellular Implants for Recombinant Protein Delivery and Therapeutic Modulation of the Immune System
Aurelien Lathuiliere et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Adaptive Immune Resistance: How Cancer Protects from Immune Attack
Antoni Ribas
CANCER DISCOVERY (2015)
Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma
Yong Feng et al.
ONCOTARGET (2015)
Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury
Christopher R. Heery et al.
CANCER IMMUNOLOGY RESEARCH (2015)
PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment
Dimitrios Mathios et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Brachyury, a Driver of the Epithelial-Mesenchymal Transition, Is Overexpressed in Human Lung Tumors: An Opportunity for Novel Interventions against Lung Cancer
Mario Roselli et al.
CLINICAL CANCER RESEARCH (2012)
The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells
Romaine I. Fernando et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Chordoma and chondrosarcoma gene profile: implications for immunotherapy
Joseph H. Schwab et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
分享论文
